Communiqués Pulse Biosciences, Inc.

Actions

PLSE

US74587B1017

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
12,38 ^USD	-14,88 %		+7,19 %	+1,14 %

14/05	Pulse Biosciences, Inc. annonce des changements de PDG	CI
14/05	Pulse Biosciences, Inc. annonce des changements au sein de son équipe de direction	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PULSE BIOSCIENCES, INC. ANNOUNCES COMMENCEMENT OF RIGHTS OFFERING	05/06	AQ
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000	20/05	BU
PULSE BIOSCIENCES CELLFX NANOSECOND PULSED FIELD ABLATION TECHNOLOGY TO BE FEATURED IN SEVERAL PRESENTATIONS AT THE HEART RHYTHM SOCIETY 2024 ANNUAL MEETING	17/05	AQ
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting	16/05	BU
Pulse Biosciences Enhances Executive Leadership Team	14/05	BU
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	09/05	BU
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results	07/05	BU
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000	02/05	BU
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024	24/04	BU
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results	28/03	BU
Pulse Biosciences Announces Plans to Initiate a Rights Offering	28/03	BU
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024	14/03	BU
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System	08/03	BU
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY	15/02	AQ
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study	14/02	BU
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium	31/01	BU
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp	02/01	BU
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter	20/12	BU
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode	21/11	BU
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference	15/11	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Pulse Biosciences, Inc.

Actions

PLSE

US74587B1017

Communiqués

Filtres